79
Participants
Start Date
January 31, 2016
Primary Completion Date
April 29, 2022
Study Completion Date
April 29, 2022
Spironolactone
Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
Placebo
Placebo
University Hospitals Cleveland Medical Center, Cleveland
University of Maryland
OTHER
University of Toronto
OTHER
Winthrop University
OTHER
University Hospitals Cleveland Medical Center
OTHER